Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392298 | 0.87 | FLT1 (0.51) | MEN1KMT2AMRGPRX4ALDH1A1MAPT | |
| SCHEMBL11520744 | 0.84 | CA12 (0.46) | LMNASMN1; SMN2MRGPRX4ALDH1A1MAPT | |
| SCHEMBL4463502 | 0.83 | KMT2A (0.49) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL27944765 | 0.83 | CYP4F2 (0.58) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL26717187 | 0.83 | PDK1 (0.42) | MRGPRX4PPARGVCAM1ARFLT1 | |
| SCHEMBL1321345 | 0.81 | ALDH1A1 (0.44) | LMNASMN1; SMN2MRGPRX4ALDH1A1KDM4E | |
| SCHEMBL30373299 | 0.81 | ALDH1A1 (0.44) | LMNASMN1; SMN2MRGPRX4ALDH1A1KDM4E | |
| SCHEMBL4314458 | 0.81 | NAMPT (0.41) | LMNAMRGPRX4ALDH1A1MAPTTSHR | |
| SCHEMBL546514 | 0.81 | CA12 (0.61) | MEN1KMT2ALMNASMN1; SMN2TSHR | |
| SCHEMBL23898723 | 0.81 | GPR35 (0.45) | LMNAMRGPRX4ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260174-A | 5- (pyrazole-4-yl) -1,2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2022-11-01 | — | — | CN | claimed |
| CN-111943944-B | Ethylthio-containing pyridine-bis-1, 2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2021-11-23 | — | — | CN | claimed |
| CN-112062759-B | Ethylsulfonyl-containing pyridine-1, 2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2021-11-23 | — | — | CN | claimed |
| CN-111592533-B | 1,2, 4-oxadiazole bipyridyl substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2021-08-24 | — | — | CN | claimed |
| CN-112062759-A | Ethylsulfonyl-containing pyridine-1, 2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2020-12-11 | — | — | CN | claimed |
| CN-111943944-A | Ethylthio-containing pyridine-bis-1, 2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2020-11-17 | — | — | CN | claimed |
| CN-111592533-A | 1,2, 4-oxadiazole bipyridyl substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2020-08-28 | — | — | CN | claimed |
| EP-4653053-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4426434-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-12 | — | — | US | disclosed |
| CN-119677720-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4490147-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | MEN1 4646/4885KMT2A 4230/4885LMNA 2403/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | MEN1 3960/4885KMT2A 2012/4885LMNA 4568/4885 |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | MEN1 4630/4885KMT2A 4163/4885LMNA 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.